|SRI's Polly Chang|
SRI International's CRO division signed a deal with the National Institutes of Health that could bring in up to $100 million over 5 years, agreeing to help develop therapies designed to treat the effects of radiation exposure.
Under the contract, SRI Biosciences is on hand to provide its drug development services to NIH's National Institute of Allergy and Infectious Diseases as it works on early-stage therapies attacking radiation expsure from multiple angles. NIAID has in the past sponsored R&D programs targeting radiation-induced hematopoietic, gastrointestinal, pulmonary and cutaneous injuries, SRI said, and the CRO believes it has the capacity and scientific know-how to move such projects forward.
"SRI has an extensive track record of drug development and basic radiation biology research, and this project fits perfectly within our broad but very deep range of product development capabilities," Polly Chang, SRI's head of toxicology, said in a statement.
The company's latest agreement follows a $49 million contract with NIAID signed last year, tasking SRI with helping develop new treatments for HIV.
SRI, a nonprofit research center, has been expanding the capabilities of its in-house CRO over the past few years, in 2014 opening a Biosciences-devoted Phase I unit in Michigan to make room for more clinical contracts.
- read the statement